A major challenge with immune checkpoint inhibitors are tumors that harbor an “immune-excluded” microenvironment, characterized by CD8 + T cells that have accumulated but not efficiently infiltrated into the center, in large part due to the presence of reactive stroma driven by TGFβ signaling.23 Together, these findings suggest that targeting LRRC15 with [177Lu]Lu-DUNP19 could remodel the tumor microenvironment, potentially creating an opportunity to combine this radiotherapeutic agent with immune checkpoint inhibitors. The gene discussed is TGFB1; the disease is neoplasm.